The Philadelphia Inquirer Interviews Dr. Sara Jane Ward about Her Recently Published Research on Novel CBD Analog KLS-13019

The Philadelphia Inquirer interviewed Sara Jane Ward, PhD, Assistant Professor of Neural Sciences and Assistant Professor in the Center for Substance Abuse Research at the Lewis Katz School of Medicine at Temple University, about a recent study published online in the British Journal of Pharmacology. The work by Dr. Ward, who is the senior investigator, and colleagues suggests a novel CBD analog known as KLS-13019 may help overcome the low bioavailability of cannabidiol, or CBD. Studies have shown CBD reduces pain sensation in animals, but its ability to do so in humans is limited by its low bioavailability, or the extent to which the drug successfully reaches its site of action. Dr. Ward and colleagues also found that KLS-13019, relative to CBD, could greatly reduce pain sensitivity in animals with chemotherapy-induced peripheral neuropathy, reverse neuropathy that was already established, and may reduce opioid cravings.